Leadership

Ken Ferry - Chief Executive Officer

As Chief Executive Officer of iCAD, Kenneth M. Ferry brings two decades of extensive experience in the management and leadership of healthcare technology organizations, with more than a decade of direct responsibility to the organizations’ P&L.

Mr. Ferry’s previous experience has clearly demonstrated his ability to lead unprecedented growth. He was most recently Senior Vice President and General Manager for the Global Patient Monitoring business for Philips Medical Systems, the market leader in a $2.5 billion industry. In this role he was responsible for Research & Development, Marketing, Business Development, Supply Chain and Manufacturing, Quality and Regulatory, Finance and Human Resources.  Mr. Ferry was named a Senior Vice President at Philips Medical Systems Division in 2001.

From 1983 to 2001, Mr. Ferry served in a number of management positions with Hewlett Packard and Agilent Technologies. As a Vice President and General Manager in the Hewlett Packard / Agilent Technologies Healthcare Solutions Group, he was one of the key executives responsible for the sale of Agilent’s Medical Solutions Group to Philips in August 2001. Prior to this, beginning in 1997, he served as Vice President and General Managaer of North American Field Operations for Hewlett Packard and Agilent Technologies. He was responsible for sales, service, and marketing for Patient Monitoring, Cardiac Ultrasound, Defibrillation, Diagnostic EKG and Information Technology solutions.

In addition to his role as Chief Executive Officer, Mr. Ferry also serves as a member of iCAD’s Board of Directors. Mr. Ferry is a graduate of Boston College, School of Management.

Richard Christopher –  Executive Vice President, Chief Financial Officer

Richard Christopher holds the positions of Executive Vice President and Chief Financial Officer for iCAD. In his most recent previous role, Mr. Christopher served as Chief Financial and Operating Officer of Caliber Imaging & Diagnostics, Inc. Prior to this, Mr. Christopher was Vice President, Finance and Chief Financial Officer of DUSA Pharmaceuticals, Inc., a NASDAQ-listed specialty dermatology company focused on the treatment of precancerous skin lesions. He joined DUSA in 2000 and held a series of positions of increasing responsibility, including serving as Chief Financial Officer from 2005 through its acquisition and integration into Sun Pharmaceuticals Industries Limited in 2013. He received a Master’s of Science Degree in Accounting from Suffolk University and a Bachelor’s of Science Degree in Finance from Bentley University.

Stacey Stevens - Executive Vice President, Chief Strategy and Commercial Officer

Stacey Stevens holds the position of Executive Vice president, Chief Strategy and Commercial Officer for iCAD. In previous roles she has served in a variety of sales, business development, and marketing management positions with Philips Medical Systems, Agilent Technologies and Hewlett Packard's Healthcare Solutions Group (which was acquired in 2001 by Philips Medical Systems). She most recently held the position of Vice President, Marketing Planning at Philips Medical Systems, where she was responsible for the leadership of all global marketing planning functions for Philips' Healthcare Business. From 2003 to 2005, she was Vice President of Marketing for the Cardiac and Monitoring Systems Business Unit of Philips where she was responsible for all marketing and certain direct sales activities for the America 's Field Operation. Prior to that, Stevens held several key marketing management positions in the Ultrasound Business Unit of Hewlett-Packard/Agilent and Philips Medical Systems.

Ms. Stevens earned a Bachelor of Arts Degree in Political Science from the University of New Hampshire, and an MBA from Boston University’s Graduate School of Management.

Jonathan Go - Senior Vice President of Research & Development

Jonathan Go brings more than twenty five years of software development experience in the medical industry to his position as Senior Vice President of Research and Development at iCAD.

Prior to joining iCAD, Go served as Vice President of Engineering at Merge eMed, a provider of RIS/PACS solutions for imaging centers, specialty practices and hospitals. At Merge eMed, Go was responsible for software development, product management, testing, system integration and technical support for all of eMed's products.

Before joining Merge eMed, Go was Director of Engineering at Cedara Software in Toronto. Cedara Software is focused on the development of custom engineered software applications and development tools for the medical imaging OEMs. At Cedara, Go built the workstation program, developing multiple specialty workstations that have been adopted by a large number of OEM partners.

Mr. Go earned a Bachelor of Science in Electrical Engineering from the University of Michigan and a Masters of Science in Electrical Engineering and Biomedical Engineering from the University of Michigan.

Board of Directors

Dr. Lawrence Howard

Chairman of the Board, General Partner, Hudson Ventures, LP

Dr. Lawrence Howard was appointed Chairman of the Board in 2007 and has been a director of the Company since November 2006.  Dr. Howard has been, since March 1997, a general partner of Hudson Ventures, L.P. (formerly known as Hudson Partners, L.P.), a limited partnership that is the general partner of Hudson Venture Partners, L.P. (“HVP”), a limited partnership that is qualified as a small business investment company.  Since March 1997, Dr. Howard has also been a managing member of Hudson Management Associates LLC, a limited liability company that provides management services to HVP.  Since November 2000, Dr. Howard has been a General Partner of Hudson Venture Partners II, and a limited partner of Hudson Venture II, L.P.  Dr. Howard was a co-founder of Presstek, Inc. ("Presstek"), which was a public company which had developed proprietary imaging and consumables technologies for the graphic arts industry. Dr. Howard served in various officer positions at Presstek from October 1987 to June 1993, lastly as its Chief Executive Officer. Dr. Howard served on the Presstek Board of Directors for over twenty years. Since 2012 Dr. Howard has worked as a consultant to The Villages, the largest retirement community in the U.S., assisting them in building a "state of the art" healthcare delivery system. Dr. Howard also served as the President of the Board of Trustees of Columbia Grammar and Preparatory School from 2008 until 2011, where he remains as Chairman Emeritus and a member of that board. Dr. Howard also serves on the University of New Hampshire Foundation Board of Trustees.

Ken Ferry

Chief Executive Officer

As Chief Executive Officer of iCAD, Kenneth M. Ferry brings two decades of extensive experience in the management and leadership of healthcare technology organizations, with more than a decade of direct responsibility to the organizations’ P&L.

Mr. Ferry’s previous experience has clearly demonstrated his ability to lead unprecedented growth. He was most recently Senior Vice President and General Manager for the Global Patient Monitoring business for Philips Medical Systems, the market leader in a $2.5 billion industry. In this role he was responsible for Research & Development, Marketing, Business Development, Supply Chain and Manufacturing, Quality and Regulatory, Finance and Human Resources.  Mr. Ferry was named a Senior Vice President at Philips Medical Systems Division in 2001.

From 1983 to 2001, Mr. Ferry served in a number of management positions with Hewlett Packard and Agilent Technologies. As a Vice President and General Manager in the Hewlett Packard / Agilent Technologies Healthcare Solutions Group, he was one of the key executives responsible for the sale of Agilent’s Medical Solutions Group to Philips in August 2001. Prior to this, beginning in 1997, he served as Vice President and General Manager of North American Field Operations for Hewlett Packard and Agilent Technologies. He was responsible for sales, service, and marketing for Patient Monitoring, Cardiac Ultrasound, Defibrillation, Diagnostic EKG and Information Technology solutions.

In addition to his role as Chief Executive Officer, Mr. Ferry also serves as a member of iCAD’s Board of Directors. Mr. Ferry is a graduate of Boston College, School of Management.

Rachel F. Brem, MD

Director of Breast Imaging and Intervention

Professor & Vice Chair, Department of Radiology

The George Washington University Medical Center

Dr. Rachel Brem is currently the Director of Breast Imaging and Intervention, Professor of Radiology and the Vice-Chairman in the Department of Radiology at The George Washington University Medical Center, positions she has held since 2000.  From 1991 to 1999, Dr. Brem was previously the Director of Breast Imaging at the John Hopkins Medical Institution.  Dr. Brem’s research includes Minimally Invasive Breast Biopsy, New Technologies for the Earlier Diagnosis of breast cancer including Computer Aided Detection, as well as Nuclear Medicine Imaging of the Breast and Electrical Impedance Imaging of the Breast.

Anthony F. Ecock

General Partner Welsh, Carson, Anderson and Stowe

Anthony Ecock is a General Partner with the private equity investment firm Welsh, Carson, Anderson & Stowe ("WCAS"), which he joined in 2007.    He has 28 years of experience in the healthcare field with 8 years in senior management positions at leading healthcare technology companies.  At WCAS, Mr. Ecock leads the Resources Group, a team responsible for helping its 25 portfolio companies identify and implement initiatives to increase growth, earnings and cash flow.  Before joining WCAS, he served as Vice President and General Manager of GE Healthcare’s Enterprise Sales organization from 2003 to 2007.  From 1999 to 2003, he served as Senior Vice President and Global General Manager of Hewlett Packard’s, then Agilent’s and finally Philips’ Patient Monitoring divisions.  Mr. Ecock spent his early career at the consulting firm of Bain & Company, where he was a Partner in the healthcare and technology practices and Program Director for Consultant Training.

Robert Goodman, MD

Thomas Jefferson University

Dr. Robert Goodman is a Professor of Radiation Oncology and a physician member of the Business Development Group in the Radiation Oncology department at the University of Pennsylvania School of Medicine.

From 2014-2016, Dr. Goodman served as senior advisor to the President at the Thomas Jefferson University in Philadelphia.  Prior to joining Jersey City Radiation Oncology, from 1998-2011, Dr. Goodman served as the chair of Radiation Oncology at St. Barnabas Medical Center. From 1977 to 1990, Dr. Goodman served as the Pancoast Professor and Chair of the Department of Radiation Oncology at the University of Pennsylvania.  Dr. Goodman also has served as Acting Executive Director of the Hospital of the University of Pennsylvania.  He has published extensively in the oncology literature in highly respected peer-reviewed journals and has co-authored a textbook on breast cancer.

Steven Rappaport

Partner, RZ Capital, LLC

Steven Rappaport has been a partner of RZ Capital, LLC since July 2002, a private investment firm that also provides administrative services for a limitied number of clients.  From March 1995 to July 2002, Mr. Rappaport was Director, President and Principal of Loanet, Inc., an online real-time accounting service used by brokers and institutions to support domestic and international securities borrowing and lending activities.  Loanet, Inc., was acquired by SunGard Data Systems in May 2001. Mr. Rappaport is currently serving as an independent director of a number of open and closed end Mutual Funds of which Credit Suisse and Aberdeen Management serve as the investmnet adviser. He is currently a Director of a number of private companies and several not for profit entities. He previously served, until 2012 as a Director of Presstek when it was sold and taken private.

Andrew H. Sassine, Director

Andrew H. Sassine has served on our Board of Directors since 2015.  Mr. Sassine also serves on the Board of Directors of NASDAQ listed Gemphire Therapeutics, Inc. (GEMP) an early-stage cardiovascular drug company formed by a licensing agreement with Pfizer, Inc.  He is Chairman of the Board of privately held ComHear Inc., a digital audio software and device company.  Mr. Sassine previously served on the Boards of Acorn Energy, Inc., and FluroPharma Medical Inc. (FMPI).

Mr. Sassine served in various positions at Fidelity Investments from 1999 to 2012, including, most recently as Portfolio Manager.  Between 2004 and 2011, he managed the Fidelity Small Cap Stock Fund, the Fidelity International Small Cap Opportunities Fund and the Fidelity Advisor International Small Cap Opportunities Fund. Mr. Sassine joined Fidelity as a high yield research analyst covering the Telecommunications, Satellite, Technology, Defense and Aerospace, and Restaurant Industries and in 2001, joined the international group as a research analyst covering small and mid-cap international stocks. Prior to joining Fidelity, he served as a vice president in the Acquisition Finance Group at Fleet National Bank.

Mr. Sassine has been a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors since 2009 and served on the Board of Trustees at the Clarke Schools for Hearing and Speech between 2009 and 2014.  Mr. Sassine earned a Bachelor of Arts degree at the University of Iowa in 1987 and an MBA from the Wharton School at the University of Pennsylvania in 1993.

Somu Subramaniam

Managing Partner and co-founder of New Science Ventures

Somu Subramaniam is currently a Managing Partner and co-founder of New Science Ventures, a New York-based venture capital firm that invests in both early and late stage companies, using novel scientific approaches to address significant unmet needs and create order of magnitude improvements in performance. He serves on the Board of Directors of Achronix Semiconductor Corporation, Ralexar Therapeutics, Ario Pharmaceuticals, Cambridge Epigenetix, Dali Wireless, Oxyrane, Resolve Therapeutics, Svelte Medical Systems, Vascular Therapies, Escalier Therapeutics, Oppilan Therapeutics, Zeotap, and iCad. Somu has also served on the Boards of Ception (acquired by Cephalon), BioVex (acquired by Amgen), Lightwire (acquired by Cisco). Prior to starting New Science Ventures in 2004, Mr. Subramaniam was a Director at McKinsey & Co. and at various times led their Strategy Practice, Technology Practice and Healthcare Practice. While at McKinsey, he advised leading multinational companies in the pharmaceuticals, medical devices, biotechnology, photonics, software and semiconductor industries. He was also a member of McKinsey’s Investment Committee. We believe Mr. Subramaniam’s qualifications to serve on our Board include his extensive financial expertise combined with his experience as an executive officer, partner, and director.

Elliot Sussman, MD

Professor of Medicine at the University of South Florida College of Medicine

Dr. Elliot Sussman, is Chair of the Board of The Villages Health and a Professor of Medicine at the University of South Florida College of Medicine.  From 1993 to 2010, Dr. Sussman served as President and Chief Executive Officer of Lehigh Valley Health Network.  Dr. Sussman served as a Fellow in General Medicine and a Robert Wood Johnson Clinical Scholar at the University of Pennsylvania and trained as a resident at the Hospital of the University of Pennsylvania.  Dr. Sussman is a director and the Chairperson of the compensation committee of the Board of Directors of Universal Health Realty Income Trust, a public company primarily engaged in investing in healthcare and human service-related facilities.  We believe Dr. Sussman’s qualifications to serve on our board include his experience as a Chief Executive Officer of a leading healthcare network, combined with his medical background and his understanding of our products and market.